Grant of share options, issue of equity and TVR

10 July 2018

Evgen Pharma plc

("Evgen" or "the Company")

Grant of share options, issue of equity and total voting rights

Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions announces that Sally Ross, the Company's Clinical Development Officer, has been granted nil cost options over a total of 368,304 ordinary shares in the Company.  The options are exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

The number of nil cost options awarded has been calculated by reference to the three month average share price to 3 July 2018.  These nil cost options are subject to the rules of the LTIP and will vest based on share price performance between the date of grant and the third anniversary of grant.

Issue of Equity

In addition, the Company announces that it has received a notice to exercise options over 80,000 ordinary shares in the Company.  The options were granted under an individual option agreement and have an exercise price of 7.3 pence per share.  Accordingly, the Company has issued and allotted 80,000 new ordinary shares of 0.25 pence each ("New Ordinary Shares").  The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares.  Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 12 July 2018.  

Total Voting Rights

There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 93,356,858.  This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/